Exagen CEO and leadership

Fortunato Ron Rocca is a President/CEO at EXAGEN INC., Board Member at Interpace Diagnostics Group Inc, and Board Member at EXAGEN INC. and is based in Greater San Diego Area. He has worked as General Manager at Alpharma, VP:Sales & Marketing at Prometheus Biosciences, and GM at Prometheus Laboratories Inc. Fortunato studied at Towson University.

Waneta Tuttle is a Board Member at EXAGEN INC., Fund Manager at Tramway Venture Partners, and Board Member at MGI PHARMA INC. She has worked as Board Member at Natl Center for Genome Resrch, Chief Executive Officer at Phdx Systems, and VP/COO at The Lovelace Foundation. Waneta works or has worked as MEMBER at Charles Stark Draper Laboratories.

Mark Hazeltine has served as our Chief Operating Officer since March 2021 and served in multiple key leadership roles including General Manager, Senior Vice President of Finance and Corporate Development, VP of Finance, and Sr. Director of Financial Planning & Analysis since 2015. Prior to joining Exagen, Mr. Hazeltine served as Director of Financial Planning and Analysis and Director of Financial Business Processes at CareFusion, a medical technology corporation. Mr. Hazeltine also worked in multiple management roles at multinational organizations including Kyocera and Qualcomm. Mr. Hazeltine received his Bachelor of Business Administration degree from the University of San Diego and Master of Business Administration degree from the Marshall School of Business at the University of Southern California.

Debra Jeske Zack, M.D., Ph.D., has served as Chief Medical Officer since March 2020. Dr. Zack is a board-certified rheumatologist with broad experience as a strategic biopharmaceutical executive in the development of therapeutics for autoimmune disease and will oversee the overall strategy and execution of the company’s clinical development plans. She has extensive experience leading research, clinical development and medical affairs teams focusing on autoimmune disorders. Prior to joining Exagen, Dr. Zack served as Vice President, Clinical Development at Xencor, Inc.; Executive Director, Medical Scientific Leader, Biotherapeutics Development Unit at Novartis; and various positions in basic research, clinical development and medical affairs at Amgen. She was an associate professor treating rheumatology patients for 10 years at UCLA prior to joining industry. She received her undergraduate degree from Texas Christian University and her M.D. and Ph.D. from the University of Texas Southwestern in Dallas before completing her residency and rheumatology fellowship at the UCLA School of Medicine.

Waneta Tuttle is a Board Member at EXAGEN INC., Fund Manager at Tramway Venture Partners, and Board Member at MGI PHARMA INC. She has worked as Board Member at Natl Center for Genome Resrch, Chief Executive Officer at Phdx Systems, and VP/COO at The Lovelace Foundation. Waneta works or has worked as MEMBER at Charles Stark Draper Laboratories.

Fortunato Ron Rocca is a President/CEO at EXAGEN INC., Board Member at Interpace Diagnostics Group Inc, and Board Member at EXAGEN INC. and is based in Greater San Diego Area. He has worked as General Manager at Alpharma, VP:Sales & Marketing at Prometheus Biosciences, and GM at Prometheus Laboratories Inc. Fortunato studied at Towson University.